NBSE - NeuBase Therapeutics Inc Stock Price, Fair Value and News

0.41USD+0.01 (+2.50%)Delayed as of 08 May 2024, 09:48 am ET

Market Summary

USD0.41+0.01

Delayedas of 08 May 2024, 09:48 am

2.50%

NBSE Stock Price

View Fullscreen

NBSE RSI Chart

NBSE Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.12

Price/Sales (Trailing)

3.01

EV/EBITDA

0.88

Price/Free Cashflow

-0.11

NBSE Price/Sales (Trailing)

NBSE Profitability

EBT Margin

-2482.14%

Return on Equity

-150.27%

Return on Assets

-73.73%

Free Cashflow Yield

-925.78%

NBSE Fundamentals

NBSE Revenue

Revenue (TTM)

533.3K

Rev. Growth (Yr)

52.68%

Rev. Growth (Qtr)

40.39%

NBSE Earnings

Earnings (TTM)

-13.7M

Earnings Growth (Yr)

76.14%

Earnings Growth (Qtr)

47.17%

Breaking Down NBSE Revenue

52 Week Range

0.41

(Low)(High)

Last 30 days

Last 90 days

-39.1%

Trailing 12 Months

121.1%

How does NBSE drawdown profile look like?

NBSE Financial Health

Current Ratio

2.87

NBSE Investor Care

Shares Dilution (1Y)

131.03%

Diluted EPS (TTM)

-7.7

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	407.5K	533.3K	0
2022	80.6K	114.6K	148.6K	294.9K
2021	28.1K	20.3K	12.6K	46.6K
2015	800.2K	418.0K	35.8K	0
2014	962.2K	1.5M	1.6M	1.2M
2013	959.7K	1.0M	1.1M	0
2012	0	0	875.9K	0
2011	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NeuBase Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 18, 2023	symetryx corp	sold	-	-	-	-
Sep 18, 2023	symetryx corp	sold	-59,500	1.19	-50,000	-
Sep 15, 2023	symetryx corp	sold	-130,205	1.26	-103,337	-
Sep 14, 2023	symetryx corp	sold	-185,916	1.44	-129,108	-
Sep 11, 2023	symetryx corp	sold	-4,861	1.44	-3,376	-
Sep 08, 2023	symetryx corp	sold	-197,136	1.53	-128,847	-
Sep 07, 2023	symetryx corp	sold	-134,734	1.8	-74,852	-
Sep 01, 2023	symetryx corp	bought	59,732	0.978	61,076	-
Aug 02, 2023	stephan dietrich a	acquired	2,051	0.022	93,234	founder and ceo
Mar 16, 2023	branning todd p.	acquired	-	-	54,200	chief financial officer

Which funds bought or sold NBSE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-4.00	5.00	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	-2.00	16.00	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-2,462	14,048	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-103	595	-%
Feb 14, 2024	Kestra Advisory Services, LLC	reduced	-8.34	-3,442	12,194	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-10,746	-	-%
Feb 14, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	unchanged	-	-2,016	11,509	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	new	-	15,604	15,604	-%
Feb 14, 2024	GREENLIGHT CAPITAL INC	unchanged	-	-17,685	100,912	-%

Are Funds Buying or Selling NBSE?

Are funds buying NBSE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NBSE

No. of Funds

Unveiling NeuBase Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	greenlight capital inc	1.7%	63,579	SC 13G/A
Sep 20, 2023	symetryx corp	3.5%	0	SC 13D/A
Sep 14, 2023	symetryx corp	9.1%	472,926	SC 13D/A
Aug 31, 2023	symetryx corp	13.8%	428,444	SC 13D
Jan 27, 2023	kershner trading americas,llc	4.46%	1,497,226	SC 13G/A
Feb 14, 2022	greenlight capital inc	3.9%	1,271,596	SC 13G/A
Feb 16, 2021	greenlight capital inc	4.1%	945,196	SC 13G/A
Dec 29, 2020	kershner trading americas,llc	-	0	SC 13G/A
May 01, 2020	hirschman orin	2.44%	563,972	SC 13G/A

Recent SEC filings of NeuBase Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	DEFA14A	DEFA14A
May 03, 2024	8-K	Current Report
Apr 09, 2024	DEF 14A	DEF 14A
Apr 05, 2024	8-K	Current Report
Mar 25, 2024	PRE 14A	PRE 14A
Mar 07, 2024	8-K	Current Report
Feb 23, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to NeuBase Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

NeuBase Therapeutics Inc News

Latest updates

NeuBase Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q3	2013Q2	2013Q1	2012Q3
Revenue	40.4%	162,924	116,048	147,604	106,710	37,147	3,445	1,254	3,991	6,729	9,466	-	91,872	183,743	275,615	367,486	628,152	400,804	168,165	319,063	74,149	517,211
Operating Expenses	-23.7%	2,813,176	3,687,945	4,600,270	7,723,381	8,360,608	9,929,383	7,304,967	7,169,190	8,839,094	5,895,769	-	-	-	3,923,987	3,076,632	2,056,416	-	-	-	-	-
S&GA Expenses	-50.0%	1,203,020	2,403,661	2,596,412	2,236,325	3,603,999	3,093,713	2,935,710	3,369,003	3,470,104	2,721,640	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-69.8%	387,564	1,284,284	1,351,407	5,487,056	4,756,609	6,835,670	4,369,257	3,800,187	2,480,961	3,174,129	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	23.2%	-23.48	-30.56	-42.19	-83.78	-108	-156	-272	-1,020	-635	-462	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-83.3%	122	730	1,868	2,693	2,819	3,316	15,219	13,059	3,074	6,460	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-3,881,673	-3,345,997	-3,400,548	-4,598,337	-3,089,856	-2,050,632	-1,968,251	-1,803,447	-1,338,431	-292,258	-
EBT Margin	23.6%	-24.82	-32.48	-44.89	-89.10	-115	-164	-284	-1,054	-651	-471	-	-	-	-	-	-	-	-	-	-	-
Net Income	47.2%	-1,821,112	-3,446,794	-4,369,039	-7,631,888	-8,491,717	-9,924,029	-7,728,816	-7,158,432	-8,662,869	-5,521,569	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	46.3%	-25.75	-47.95	-103	-227	-290	-415	-624	-2,024	-1,130	-644	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	45.0%	-2,002,565	-3,643,732	-5,737,692	-6,666,860	-9,083,671	-8,340,824	-5,392,322	-5,783,781	-6,823,904	-3,729,982	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-16.6%	19.00	22.00	21.00	26.00	33.00	40.00	49.00	57.00	64.00	69.00	27.00	31.00	34.00	38.00	8.00	10.00	13.00	9.00	0.00	6.00	12.00
Current Assets	-14.0%	13.00	16.00	14.00	18.00	25.00	32.00	40.00	48.00	55.00	60.00	25.00	29.00	33.00	37.00	6.00	9.00	11.00	2.00	2.00	3.00	0.00
Cash Equivalents	-14.8%	13.00	15.00	14.00	17.00	23.00	30.00	39.00	47.00	53.00	59.00	24.00	28.00	32.00	36.00	6.00	8.00	10.00	0.00	0.00	0.00	0.00
Net PPE	-94.7%	0.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-14.5%	9.00	11.00	7.00	7.00	10.00	10.00	11.00	10.00	10.00	9.00	4.00	2.00	3.00	3.00	4.00	3.00	3.00	1.00	2.00	1.00	0.00
Current Liabilities	-24.1%	5.00	6.00	2.00	2.00	4.00	4.00	5.00	4.00	4.00	3.00	-	-	3.00	-	-	-	3.00	1.00	1.00	1.00	0.00
Shareholder's Equity	-18.8%	9.00	11.00	14.00	18.00	23.00	30.00	38.00	47.00	54.00	60.00	24.00	29.00	31.00	35.00	4.00	7.00	10.00	8.00	9.00	10.00	11.00
Retained Earnings	-1.6%	-116	-114	-111	-107	-102	-95.11	-86.62	-76.70	-68.97	-61.81	-53.15	-47.63	-43.56	-39.68	-35.88	-31.51	-26.17	-124	-3.56	-1.53	-0.04
Additional Paid-In Capital	-0.2%	126	126	126	125	126	125	125	124	123	122	77.00	76.00	75.00	74.00	40.00	39.00	36.00	132	2.00	1.00	-517*
Shares Outstanding	98.6%	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	58.00	-	-	-	-	-	-	-	161	-	-	-	6.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	45.0%	-2,002	-3,643	-3,447	-5,687	-6,638	-8,913	-8,192	-5,268	-5,442	-6,130	-3,520	-3,780	-3,567	-2,885	-1,815	-2,441	-2,450	-135	-244	-14.93	-596
Share Based Compensation	-219.3%	-292	245	317	-509	511	641	953	793	953	625	942	1,177	1,140	1,211	1,339	1,504	6,592	820	1,254	293	73.00
Cashflow From Investing	-	-	-	-4.95	-49.84	-28.81	-170	-148	-123	-351	-1,793	-209	-208	-353	-201	-93.52	-68.40	-305	-250	-31.65	-97.46	20.00
Cashflow From Financing	-103.8%	-174	4,546	-88.42	-28.64	-27.30	-27.62	-27.12	-174	-155	42,520	-	-26.11	-10.84	33,239	-49.49	-73.43	13,002	-8.81	601	-14*	-108
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14*	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NBSE Income Statement

2023-09-30

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
OPERATING EXPENSES
General and administrative	$ 1,203,020	$ 2,236,325	$ 6,523,996	$ 8,934,037
Research and development	387,564	5,487,056	2,912,094	17,079,335
Restructuring and impairment	1,222,592	0	1,229,319	0
TOTAL OPERATING EXPENSES	2,813,176	7,723,381	10,665,409	26,013,372
LOSS FROM OPERATIONS	(2,813,176)	(7,723,381)	(10,665,409)	(26,013,372)
OTHER INCOME (EXPENSE)
Interest expense	(122)	(2,693)	(3,206)	(8,828)
Interest income	162,924	106,710	457,349	147,302
Loss on issuance of common stock and warrants	(660)	0	(1,312,212)	0
Change in fair value of warrant liabilities	810,895	0	2,241,246	0
Other income (expense), net	19,027	(12,524)	(78,787)	(172,736)
Total other income (expense), net	992,064	91,493	1,304,390	(34,262)
NET LOSS	$ (1,821,112)	$ (7,631,888)	$ (9,361,019)	$ (26,047,634)
BASIC LOSS PER SHARE (in dollars per share)	$ (0.66)	$ (4.73)	$ (4.57)	$ (16.08)
DILUTED LOSS PER SHARE (in dollars per share)	$ (0.66)	$ (4.73)	$ (4.57)	$ (16.08)
WEIGHTED AVERAGE SHARES OUTSTANDING:
BASIC (in shares)	2,757,576	1,614,156	2,046,477	1,620,344
DILUTED (in shares)	2,757,576	1,614,156	2,046,477	1,620,344

NBSE Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 12,570,359	$ 17,386,326
Assets held for sale	429,140	0
Prepaid insurance	259,583	188,266
Other prepaid expenses and current assets	92,950	391,655
Total current assets	13,352,032	17,966,247
EQUIPMENT, net	79,665	1,934,100
OTHER ASSETS
Right-of-use asset, operating lease asset	5,064,184	5,409,574
Security deposit	125,391	273,215
Total other assets	5,189,575	5,682,789
TOTAL ASSETS	18,621,272	25,583,136
CURRENT LIABILITIES
Accounts payable	258,644	369,505
Accrued expenses and other current liabilities	462,186	1,227,656
Warrant liabilities	3,428,601	0
Operating lease liabilities	500,817	469,118
Finance lease liabilities	0	78,987
Total current liabilities	4,650,248	2,145,266
Long-term operating lease liability	4,834,348	5,214,074
TOTAL LIABILITIES	9,484,596	7,359,340
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2023 and December 31, 2022
Common stock, $0.0001 par value; 250,000,000 shares authorized; 3,729,206 and 1,657,768 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	373	166
Additional paid-in capital	125,610,714	125,337,022
Accumulated deficit	(116,474,411)	(107,113,392)
TOTAL STOCKHOLDERS' EQUITY	9,136,676	18,223,796
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 18,621,272	$ 25,583,136

About NeuBase Therapeutics Inc

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

CEO	Dr. Dietrich A. Stephan Ph.D.
WEBSITE	neubasetherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	37

NeuBase Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for NeuBase Therapeutics Inc? What does NBSE stand for in stocks?

NBSE is the stock ticker symbol of NeuBase Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeuBase Therapeutics Inc (NBSE)?

As of Tue May 07 2024, market cap of NeuBase Therapeutics Inc is 1.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NBSE stock?

You can check NBSE's fair value in chart for subscribers.

What is the fair value of NBSE stock?

You can check NBSE's fair value in chart for subscribers. The fair value of NeuBase Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NeuBase Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NBSE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NeuBase Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether NBSE is over valued or under valued. Whether NeuBase Therapeutics Inc is cheap or expensive depends on the assumptions which impact NeuBase Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBSE.

What is NeuBase Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, NBSE's PE ratio (Price to Earnings) is -0.12 and Price to Sales (PS) ratio is 3.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBSE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on NeuBase Therapeutics Inc's stock?

In the past 10 years, NeuBase Therapeutics Inc has provided -0.44 (multiply by 100 for percentage) rate of return.